Poly (D, L-Lactide-co-Glycolide) Nanoparticles Loaded with Cerebrolysin Display Neuroprotective Activity in a Rat Model of Concussive Head Injury

被引:21
作者
Ruozi, Barbara [1 ]
Belletti, Daniela [1 ]
Forni, Flavio [1 ]
Sharma, Aruna [2 ]
Muresanu, Dafin [3 ]
Moessler, Herbert [4 ]
Vandelli, Maria A. [1 ]
Tosi, Giovanni [1 ]
Sharma, Hari S. [2 ]
机构
[1] Univ Modena & Reggio Emilia, Dept Life Sci, Lab Pharmaceut Technol, I-41100 Modena, Italy
[2] Uppsala Univ, Univ Hosp, Dept Surg Sci Anesthesiol & Intens Care Med, Lab Cerebrovasc Res, SE-75421 Uppsala, Sweden
[3] Univ Hosp, Univ Med Pharm, Dept Clin Neurosci, Cluj Napoca, Romania
[4] Ever Neuro Pharma, Oberburgau, Austria
关键词
Blood-brain barrier; brain edema; cerebrolysin; closed head injury; Poly; (D; L-lactide-co-glycolide); nanoparticles; BLOOD-BRAIN-BARRIER; WHOLE-BODY HYPERTHERMIA; NEUROTROPHIC FACTORS; SOLVENT EVAPORATION; PLGA NANOPARTICLES; MORBIDITY FACTORS; EDEMA FORMATION; DRUG-DELIVERY; PATHOLOGY; DISRUPTION;
D O I
10.2174/1871527313666140806145540
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Cerebrolysin (CBL) is a neuroprotective agent in central nervous system (CNS) injury and stimulates neurorepair processes. Several studies in our laboratory suggest that CBL administered through nanowired technology may have superior neuroprotective efficacy in CNS trauma. In this investigation, we compared the neuroprotective efficacy of poly-lactide-co-glycolide nanoparticles (NPs) loaded with CBL vs free CBL in a rat model of concussive head injury (CHI). Free CBL or CBL loaded NPs was administered 30 min to 1 h after CHI and animals were sacrificed 5 h later. Changes in blood-brain barrier and brain edema formation were measured as parameters of neuroprotection in CHI after giving CBL alone or as the nanodelivered compound. Our results clearly show that delivery of CBL by NPs has superior neuroprotective effects following CHI as compared to normal CBL. This suggests that CBL delivered by NPs could have robust neuroprotective action in CNS trauma. These findings have potential clinical relevance with regard to nanodelivery of CBL, a feature that requires further investigation.
引用
收藏
页码:1475 / 1482
页数:8
相关论文
共 36 条
[1]  
[Anonymous], 2013, LANCET, V382, P1536
[2]   THE PREPARATION AND EVALUATION OF DRUG-CONTAINING POLY(DL-LACTIDE) MICROSPHERES FORMED BY THE SOLVENT EVAPORATION METHOD [J].
BODMEIER, R ;
MCGINITY, JW .
PHARMACEUTICAL RESEARCH, 1987, 4 (06) :465-471
[3]   PLGA nanoparticles surface decorated with the sialic acid, N-acetylneuraminic acid [J].
Bondioli, Lucia ;
Costantino, Luca ;
Ballestrazzi, Antonio ;
Lucchesi, Davide ;
Boraschi, Diana ;
Pellati, Federica ;
Benvenuti, Stefania ;
Tosi, Giovanni ;
Vandelli, Maria A. .
BIOMATERIALS, 2010, 31 (12) :3395-3403
[4]   Association between combat stress and post-concussive symptom reporting in OEF/OIF service members with mild traumatic brain injuries [J].
Cooper, Douglas B. ;
Kennedy, Jan E. ;
Cullen, Maren A. ;
Critchfield, Eda. N. ;
Amador, Ricardo R. ;
Bowles, Amy O. .
BRAIN INJURY, 2011, 25 (01) :1-7
[5]   Nanoparticulate drug carriers based on hybrid poly(D,L-lactide-co-glycolide)-dendron structures [J].
Costantino, Luca ;
Gandolfi, Francesca ;
Bossy-Nobs, Leila ;
Tosi, Giovanni ;
Gurny, Robert ;
Rivasi, Francesco ;
Vandelli, Maria Angela ;
Forni, Flavio .
BIOMATERIALS, 2006, 27 (26) :4635-4645
[6]   PLGA-based nanoparticles: An overview of biomedical applications [J].
Danhier, Fabienne ;
Ansorena, Eduardo ;
Silva, Joana M. ;
Coco, Regis ;
Le Breton, Aude ;
Preat, Veronique .
JOURNAL OF CONTROLLED RELEASE, 2012, 161 (02) :505-522
[7]  
DEY P K, 1984, Indian Journal of Physiology and Pharmacology, V28, P177
[8]   Optimization of protein encapsulation in PLGA nanoparticles [J].
Feczko, T. ;
Toth, J. ;
Dosa, Gy. ;
Gyenis, J. .
CHEMICAL ENGINEERING AND PROCESSING-PROCESS INTENSIFICATION, 2011, 50 (08) :757-765
[9]   Effect of preparative parameters on the characteristics of poly(D,L-lactide-co-glycolide) microspheres made by the double emulsion method [J].
Ghaderi, R ;
Sturesson, C ;
Carlfors, J .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1996, 141 (1-2) :205-216
[10]  
Gromova OA, 2003, ZH NEVROPATOL PSIKH, V103, P59